Certolizumab pegol: adverse event reports filed with FDA

27,395

reports as suspect product

0.1% of all reports · about 1,515 a year

2,232

reports, 12 months to June 2026

3,735 in the 12 months before

97.2%

marked serious by the reporter

56.2% across the class

11.4%

record death among outcomes, as reported

3,129 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Certolizumab pegol reports recording the termmedian drug in tumor necrosis factor blocker

1. Drug ineffectivethe medicine did not work as expected17.2%4,723
2. Rheumatoid arthritisrheumatoid arthritis, an inflammatory joint disease17%4,645
3. Off label useused for a purpose or in a way not on the label13.2%3,629
4. Fatiguetiredness11.8%3,232
5. Painpain, site not specified11.4%3,111
6. Maternal exposure during pregnancythe mother took the medicine during pregnancy10.7%2,923
7. Psoriatic arthropathy10.3%2,822
8. Arthralgiajoint pain9.1%2,484
9. Rashskin rash7.9%2,171
10. Headachehead pain7.9%2,166
11. Pneumonialung infection7.6%2,071
12. Alopeciahair loss7.4%2,016
13. Abdominal discomfortstomach discomfort7.3%1,991
14. Arthropathy6.8%1,870
15. Nauseafeeling sick6.7%1,833
16. Glossodynia6.6%1,810
17. Hypersensitivityan allergic-type reaction6.6%1,807
18. Joint swellinga swollen joint6.6%1,797
19. Systemic lupus erythematosuslupus, an autoimmune disease6.5%1,777
20. Product use issuea problem in how the product was used6.3%1,734
21. Hand deformity6.2%1,706
22. Malaisegeneral feeling of being unwell6.2%1,692
23. Contraindicated product administered6.2%1,691
24. Drug intolerancethe medicine was not tolerated6.1%1,674
25. Pemphigus6.1%1,663
26. Diarrhoealoose or frequent stools6.1%1,662
27. Infectionan infection, type not specified6.1%1,662
28. Lower respiratory tract infectiona chest infection6%1,653
29. Synovitis5.8%1,586
30. Musculoskeletal stiffnessstiffness in muscles or joints5.7%1,575

Top 30 of 2,116 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 17 drugs in the tumor necrosis factor blocker class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 1,064,042 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 35.7% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 27,395 reports.

Drugs most often listed in the same reports

Other products listed in reports where Certolizumab pegol is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the tumor necrosis factor blocker class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Certolizumab pegol as a suspect or interacting product; reports listing it only as a concomitant medication (744) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.